Ligands for LXR and FXR are under clinical development for the treatment of diabetes mellitus, high cholesterol, and obesity; and it is therefore important to balance their beneficial metabolic effects against their possible side effects on platelet reactivity and function. This evidence concerns the gene NR1H4 and obesity due to melanocortin 4 receptor deficiency.